



## **Aastrom Biosciences Receives Notification That NASDAQ Further Extends Suspension of Certain Continued Listing Requirements**

### **Aastrom Has Until September 18, 2009 to Regain Compliance**

ANN ARBOR, Mich., March 23, 2009 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of autologous adult stem cell treatments for severe chronic cardiovascular diseases, announced that the Company received Issuer Alert #2009-002 from The Nasdaq Stock Market LLC ("NASDAQ"). The Issuer Alert states that, given the continued extraordinary market conditions, NASDAQ has further suspended enforcement of the rules requiring a minimum \$1.00 per share closing bid price and a minimum market value of publicly held shares until Monday, July 20, 2009. As a result of NASDAQ further extending the suspension and the balance of 60 days remaining on Aastrom's pending compliance period at the time of the initial suspension, Aastrom now has until September 18, 2009 to regain compliance with the \$1.00 minimum closing bid price rule in order to remain listed on the Nasdaq Capital Market.

About Aastrom Biosciences, Inc.

Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. The Company's ongoing development activities focus on applying TRC technology to cardiac and vascular tissue regeneration. A Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia (CLI) patients (the RESTORE-CLI trial) are currently underway.

For more information, visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com).

The Aastrom Biosciences, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=3663>

This document contains forward-looking statements, including without limitation, statements concerning planned clinical trials and activities and anticipated timing of clinical events, product development objectives, and potential product applications, which involve certain risks and uncertainties. The forward-looking statements are also identified through use of the words "expected," "anticipated," "planned," and other words of similar meaning. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are potential patient accrual difficulties, clinical trial results, potential product development difficulties, the effects of competitive therapies, regulatory approval requirements, the availability of financial and other resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission.

CONTACT: Aastrom Biosciences, Inc.  
Investor Relations Department  
Kris M. Maly  
Kimberli O'Meara  
(734) 930-5777

Cameron & Associates  
Investors  
Kevin McGrath  
(212) 245-4577

(C) Copyright 2009 GlobeNewswire, Inc. All rights reserved.